Jacinta A. Holmes, Stuart K. Roberts, Rachel J. Ali, Gregory J. Dore, William Sievert, Geoffrey W. McCaughan, Darrell H. Crawford, Wendy S. Cheng, Martin D. Weltman, Sara Bonanzinga, Kumar Visvanathan, Vijaya Sundararajan, Paul V. Desmond, D. Scott Bowden, Gail V. Matthews, Alexander J. Thompson, on behalf of the CHARIOT Study Group – 21 January 2014 – On‐treatment anemia is associated with higher sustained virological response (SVR) rates during peginterferon plus ribavirin (RBV) therapy.

José M. Mato, M. Luz Martínez‐Chantar, Shelly C. Lu – 21 January 2014 – Medicine is expected to benefit from combining usual cellular and molecular studies with high‐throughput methods (genomics, transcriptomics, proteomics, and metabolomics). These methods, collectively known as omics, permit the determination of thousands of molecules (variations within genes, RNAs, proteins, metabolites) within a tissue, cell, or biological fluid. The use of these methods is very demanding in terms of the design of the study, acquisition, storage, analysis, and interpretation of the data.

Teresa Santantonio, Massimo Fasano, Evangelista Sagnelli, Paolo Tundo, Sergio Babudieri, Paolo Fabris, Mario Toti, Giovanni Perri, Nicoletta Marino, Eligio Pizzigallo, Gioacchino Angarano, the Acute Hepatitis C Study Group – 18 January 2014 – Therapy of acute hepatitis C (AHC) has not yet been standardized and several issues are still unresolved. This open, randomized, multicenter trial aimed to assess the efficacy and safety of a 24‐week course of pegylated IFN (Peg‐IFN) alpha‐2b versus a 12‐week course of Peg‐IFN alpha‐2b alone or with ribavirin (RBV) in AHC patients.

Ben Zhou, Yi Zhang, Fang Zhang, Yulei Xia, Jun Liu, Rui Huang, Yuangao Wang, Yanan Hu, Jingxia Wu, Changgui Dai, Hui Wang, Yanyang Tu, Xiaozhong Peng, Yiqian Wang, Qiwei Zhai – 18 January 2014 – The protein deacetylase, sirtuin 1 (SIRT1), involved in regulating hepatic insulin sensitivity, shows circadian oscillation and regulates the circadian clock. Recent studies show that circadian misalignment leads to insulin resistance (IR); however, the underlying mechanisms are largely unknown.

Ling Yang, Ekihiro Seki – 17 January 2014

Gabriel G. Malouf, Sylvie Job, Valérie Paradis, Monique Fabre, Laurence Brugières, Pierre Saintigny, Laure Vescovo, Jacques Belghiti, Sophie Branchereau, Sandrine Faivre, Aurélien Reyniès, Eric Raymond – 17 January 2014 – Fibrolamellar hepatocellular carcinoma (FLC) is a rare subtype of liver cancer occurring mostly in children and young adults. We have shown that FLC comprises two separate entities: pure (p‐FLC) and mixed‐FLC (m‐FLC), differing in clinical presentation and course.

Krasimira Aleksandrova, Heiner Boeing, Ute Nöthlings, Mazda Jenab, Veronika Fedirko, Rudolf Kaaks, Annekatrin Lukanova, Antonia Trichopoulou, Dimitrios Trichopoulos, Paolo Boffetta, Elisabeth Trepo, Sabine Westhpal, Talita Duarte‐Salles, Magdalena Stepien, Kim Overvad, Anne Tjønneland, Jytte Halkjær, Marie‐Christine Boutron‐Ruault, Laure Dossus, Antoine Racine, Pagona Lagiou, Christina Bamia, Vassiliki Benetou, Claudia Agnoli, Domenico Palli, Salvatore Panico, Rosario Tumino, Paolo Vineis, Bas Bueno‐de‐Mesquita, Petra H. Peeters, Inger Torhild Gram, Eiliv Lund, Elisabete Weiderpass, J.

Keiichi Shirasaki, Keiko Taguchi, Michiaki Unno, Hozumi Motohashi, Masayuki Yamamoto – 17 January 2014 – Hepatectomy is a standard therapy that allows liver cancer patients to achieve long‐term survival. Preceding hepatectomy, portal vein embolization (PVE) is frequently performed to increase the remnant liver size and reduce complications. Although the clinical importance of PVE is widely accepted, molecular mechanisms by which PVE leads to compensatory hypertrophy of nonembolized lobes remain elusive.

Francesco Salerno, Valentina Monti – 15 January 2014

Jia‐Hao Jiang, Yan‐Feng Liu, Ai‐Wu Ke, Fang‐Ming Gu, Yao Yu, Zhi Dai, Qiang Gao, Guo‐Ming Shi, Bo‐Yi Liao, You‐Hua Xie, Jia Fan, Xiao‐Wu Huang, Jian Zhou – 15 January 2014 – Virus‐induced hepatocarcinogenesis involves a series of histological developmental processes with the stepwise acquisition of several genetic changes that are necessary for the malignant transformation of hepatocytes. Although genetic alterations are known to be involved in the pathogenesis of hepatocellular carcinoma (HCC), little is known about the contributions of specific genes to this process.